HealthDay News — After Roux-en-Y gastric bypass (RYGB) surgery, variations in rates of diabetes remission are primarily related to differences in the definition of remission and study duration, according to a review published in Diabetes Care.
Deanna J.M. Isaman, PhD, from the University of Michigan in Ann Arbor, and colleagues conducted a literature review that identified 10 large (n >100), recent (index surgery since 2000) studies of diabetes remission after RYGB. Studies differed in definitions of remission, lengths of follow-up (1 year vs at least 3 years), reported outcomes, and risks of attrition bias.
The researchers found that reported rates of partial remission were 10 to 30 percentage points higher than rates of complete remission. Sixty-nine percent of the variability in cumulative remission rates was explained by study duration. Variability up to 87% was explained by adjustment for attrition. Three-year cumulative, complete remission rates ranged from 63% to 65%, with adjustment for attrition. However, relapse was not accounted for in these results. Accounting for relapse, attrition-adjusted, 3-year prevalent complete remission rates were 23%.
“Future studies should report both cumulative and prevalent remission to aid decision making and more easily compare studies,” the researchers wrote.
- Isaman DJM, Rothberg AE, Herman WH. Reconciliation of type 2 diabetes remission rates in studies of Roux-en-Y gastric bypass. Diabetes Care. 2016 Oct 13. doi:10.2337/dc16-0954.